Vimian Group AB (publ) (VIMGF) Stock Price & Analysis
Vimian Group AB (publ) (VIMGF) — price $4.16 (0.00%), as of the Nov 19, 2026 trading session; market cap $2.20B.
Educational signal · not a buy or sell recommendation · How to read this
Vimian Group AB (publ) · VIMGF
Vimian Group AB (publ) operates in the animal health sector, offering a range of products and services across diagnostics, pharmaceuticals, MedTech, and veterinary services. The company focuses on preventive care and chronic condition treatments for companion animals and livestock.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.16 | |
| Change on the day | 0.00% | |
| 52-week range | $2.68 – $4.16 | |
| Market capitalisation | $2.20B | — |
| Price / earnings (trailing) | 50.82 | |
| Shares traded on the day | 7.0K |
Price & events
What is Vimian Group AB (publ) (VIMGF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Vimian Group AB (publ) (VIMGF) is the company analyzed here. It employs 1,300 people and is led by Alireza Tajbakhsh. In Q3 FY2026 it reported revenue of €115M and net income of €8M. The market values it at $2.20B.
What do the latest results show for Vimian Group AB (publ) (VIMGF)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of €115M. Against analyst estimates the company has EPS beat 1 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | €115M | €8M | €0.02 (diluted) |
| Q2 FY2026 | €119M | €8M | €0.02 (diluted) |
| Q1 FY2026 | €116M | €10M | €0.02 (diluted) |
| Q4 FY2025 | €109M | €12M | €0.02 (diluted) |
What are the financial strengths and risks for Vimian Group AB (publ) (VIMGF)?
Short answer · as of
The distress and quality screens read Altman Z 3.70 · Piotroski F 6. Trailing ratios: ROE 5.4% · ROA 3.3% · current ratio 2.73 · earnings yield 1.9% · free-cash-flow yield 4.5%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VIMGF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported VIMGF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Vimian Group AB (publ) Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the VIMGF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is VIMGF a good stock to buy?
Stock Expert AI does not rate VIMGF buy, sell or hold. Vimian Group AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the VIMGF stock price today?
The last price recorded for Vimian Group AB (publ) (VIMGF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for VIMGF?
Vimian Group faces several risks inherent to the animal health industry. Intense competition from established players like Zoetis and IDEXX Laboratories could impact market share and pricing power.
What are the key factors to evaluate for VIMGF?
Evaluate VIMGF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Development of Advanced Diagnostics: Vimian's Indical Bioscience is focused on developing advanced molecular and immunodiagnostic solutions for veterinary laboratories. Not financial advice.
How frequently does VIMGF data refresh on this page?
VIMGF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven VIMGF's recent stock price performance?
Vimian Group AB (publ) (VIMGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified business model across multiple segments of the animal health market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VIMGF overvalued or undervalued right now?
The trailing P/E of Vimian Group AB (publ) (VIMGF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VIMGF before investing?
Before investing in Vimian Group AB (publ) (VIMGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com